Emerging therapeutic opportunities for skeletal restoration

Masanobu Kawai, Ulrike I. Mödder, Sundeep Khosla, Clifford J. Rosen

Research output: Contribution to journalArticle

83 Citations (Scopus)

Abstract

Osteoporosis, a syndrome characterized by thin bones and fractures, has become more prevalent in both women and men. Established therapies for treating this disorder consist primarily of drugs that prevent bone loss, such as the bisphosphonates and selective oestrogen receptor modulators. Although these drugs have been shown to reduce fractures in randomized trials, there is an urgent need for treatments that could lower fracture risk further without additional adverse effects. The introduction of parathyroid hormone (teriparatide), which significantly increases bone mineral density, albeit for a relatively short duration, raised expectations that drugs that stimulate bone formation might cure osteoporosis. After outlining current approaches for treating osteoporosis, this Review focuses on emerging therapeutic opportunities for osteoporosis that are based on recent insights into skeletal physiology. Such novel strategies offer promise not only for reducing age-related bone loss and the associated risk of fractures but also for restoring bone mineral density to healthy levels.

Original languageEnglish (US)
Pages (from-to)141-156
Number of pages16
JournalNature Reviews Drug Discovery
Volume10
Issue number2
DOIs
StatePublished - Feb 2011

Fingerprint

Osteoporosis
Bone Density
Pharmaceutical Preparations
Teriparatide
Selective Estrogen Receptor Modulators
Therapeutics
Bone Fractures
Diphosphonates
Parathyroid Hormone
Osteogenesis
Bone and Bones

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology

Cite this

Emerging therapeutic opportunities for skeletal restoration. / Kawai, Masanobu; Mödder, Ulrike I.; Khosla, Sundeep; Rosen, Clifford J.

In: Nature Reviews Drug Discovery, Vol. 10, No. 2, 02.2011, p. 141-156.

Research output: Contribution to journalArticle

Kawai, Masanobu ; Mödder, Ulrike I. ; Khosla, Sundeep ; Rosen, Clifford J. / Emerging therapeutic opportunities for skeletal restoration. In: Nature Reviews Drug Discovery. 2011 ; Vol. 10, No. 2. pp. 141-156.
@article{18283a4a8c344a7195cc2b190e510218,
title = "Emerging therapeutic opportunities for skeletal restoration",
abstract = "Osteoporosis, a syndrome characterized by thin bones and fractures, has become more prevalent in both women and men. Established therapies for treating this disorder consist primarily of drugs that prevent bone loss, such as the bisphosphonates and selective oestrogen receptor modulators. Although these drugs have been shown to reduce fractures in randomized trials, there is an urgent need for treatments that could lower fracture risk further without additional adverse effects. The introduction of parathyroid hormone (teriparatide), which significantly increases bone mineral density, albeit for a relatively short duration, raised expectations that drugs that stimulate bone formation might cure osteoporosis. After outlining current approaches for treating osteoporosis, this Review focuses on emerging therapeutic opportunities for osteoporosis that are based on recent insights into skeletal physiology. Such novel strategies offer promise not only for reducing age-related bone loss and the associated risk of fractures but also for restoring bone mineral density to healthy levels.",
author = "Masanobu Kawai and M{\"o}dder, {Ulrike I.} and Sundeep Khosla and Rosen, {Clifford J.}",
year = "2011",
month = "2",
doi = "10.1038/nrd3299",
language = "English (US)",
volume = "10",
pages = "141--156",
journal = "Nature Reviews Drug Discovery",
issn = "1474-1776",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Emerging therapeutic opportunities for skeletal restoration

AU - Kawai, Masanobu

AU - Mödder, Ulrike I.

AU - Khosla, Sundeep

AU - Rosen, Clifford J.

PY - 2011/2

Y1 - 2011/2

N2 - Osteoporosis, a syndrome characterized by thin bones and fractures, has become more prevalent in both women and men. Established therapies for treating this disorder consist primarily of drugs that prevent bone loss, such as the bisphosphonates and selective oestrogen receptor modulators. Although these drugs have been shown to reduce fractures in randomized trials, there is an urgent need for treatments that could lower fracture risk further without additional adverse effects. The introduction of parathyroid hormone (teriparatide), which significantly increases bone mineral density, albeit for a relatively short duration, raised expectations that drugs that stimulate bone formation might cure osteoporosis. After outlining current approaches for treating osteoporosis, this Review focuses on emerging therapeutic opportunities for osteoporosis that are based on recent insights into skeletal physiology. Such novel strategies offer promise not only for reducing age-related bone loss and the associated risk of fractures but also for restoring bone mineral density to healthy levels.

AB - Osteoporosis, a syndrome characterized by thin bones and fractures, has become more prevalent in both women and men. Established therapies for treating this disorder consist primarily of drugs that prevent bone loss, such as the bisphosphonates and selective oestrogen receptor modulators. Although these drugs have been shown to reduce fractures in randomized trials, there is an urgent need for treatments that could lower fracture risk further without additional adverse effects. The introduction of parathyroid hormone (teriparatide), which significantly increases bone mineral density, albeit for a relatively short duration, raised expectations that drugs that stimulate bone formation might cure osteoporosis. After outlining current approaches for treating osteoporosis, this Review focuses on emerging therapeutic opportunities for osteoporosis that are based on recent insights into skeletal physiology. Such novel strategies offer promise not only for reducing age-related bone loss and the associated risk of fractures but also for restoring bone mineral density to healthy levels.

UR - http://www.scopus.com/inward/record.url?scp=79551610971&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79551610971&partnerID=8YFLogxK

U2 - 10.1038/nrd3299

DO - 10.1038/nrd3299

M3 - Article

C2 - 21283108

AN - SCOPUS:79551610971

VL - 10

SP - 141

EP - 156

JO - Nature Reviews Drug Discovery

JF - Nature Reviews Drug Discovery

SN - 1474-1776

IS - 2

ER -